Revvity, Inc.
General ticker "RVTY" information:
- Sector: Health Care
- Industry: Medical - Diagnostics & Research
- Capitalization: $11.1B (TTM average)
Revvity, Inc. follows the US Stock Market performance with the rate: 36.6%.
Estimated limits based on current volatility of 2.1%: low 99.66$, high 103.95$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-04-17, amount 0.07$ (Y0.28%)
- Total employees count: 11000 (0.0%) as of 2025
- China accounted for 16.3% of revenue in the fiscal year ended 2024-12-29
- US accounted for 39.8% of revenue in the fiscal year ended 2024-12-29
- Top business risk factors: Economic downturns and volatility, Geopolitical risks, Market competition, Regulatory and compliance, Supply chain disruptions
- Earnings for 15 months up through Q1 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-29 to 2026-12-29
- 2024-12-29 to 2025-12-29 estimated range: [101.35$, 139.90$]
- 2025-12-29 to 2026-12-29 estimated range: [108.91$, 149.46$]
Financial Metrics affecting the RVTY estimates:
- Negative: with PPE of 23.0 at the end of fiscal year the price was very high
- Positive: 7.54 < Operating profit margin, % of 14.90
- Positive: Investing cash flow per share per price, % of 5.61 > -0.60
- Positive: 42.59 < Shareholder equity ratio, % of 61.87 <= 64.29
- Positive: 1.81 < Return on assets ratio (scaled to [-100,100]) of 2.23
- Positive: Inventory ratio change, % of -1.99 <= -0.75
- Negative: negative Industry operating cash flow (median)
Short-term RVTY quotes
Relationship graph
Long-term RVTY plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-29 |
|---|---|---|---|
| Operating Revenue | $3,311.82MM | $2,750.57MM | $2,755.03MM |
| Operating Expenses | $2,530.70MM | $2,351.08MM | $2,344.51MM |
| Operating Income | $781.12MM | $399.49MM | $410.52MM |
| Non-Operating Income | $-129.28MM | $-216.51MM | $-94.39MM |
| Interest Expense | $103.95MM | $98.81MM | $96.28MM |
| R&D Expense | $221.62MM | $216.58MM | $196.84MM |
| Income(Loss) | $651.84MM | $182.98MM | $316.13MM |
| Taxes | $139.16MM | $3.47MM | $33.05MM |
| Net Income(Loss)* | $569.18MM | $-118.38MM | $295.83MM |
| Stockholders Equity | $7,382.88MM | $7,872.74MM | $7,666.87MM |
| Inventory | $405.46MM | $428.06MM | $367.59MM |
| Assets | $14,129.85MM | $13,564.67MM | $12,392.48MM |
| Operating Cash Flow | $679.81MM | $91.27MM | $628.30MM |
| Capital expenditure | $85.63MM | $81.37MM | $86.65MM |
| Investing Cash Flow | $-132.85MM | $1,313.52MM | $776.16MM |
| Financing Cash Flow | $-661.80MM | $-947.12MM | $-1,128.23MM |
| Earnings Per Share** | $4.51 | $-0.95 | $2.41 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.